🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: GSK1265744 30mg

Found 10 matching trials

A Study to Evaluate Pharmacokinetic (PK) and Safety of GSK1265744 in Subjects With Hepatic Impairment and Control Healthy Volunteers

PHASE1

This will be a Phase 1, open-label, parallel group, two-part, single-dose a...

Status

Completed

Location

GSK Investigational Site

Start Date

2015-06-22

Trial ID

NCT02354950

Treatments Being Tested

GSK1265744 30mg

Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.

PHASE3

The purpose of this study is to evaluate if offering long-acting injectable...

Status

Not Yet Recruiting

Location

Hôpital Hôtel Dieu

Start Date

2024-04-01

Trial ID

NCT06273943

Treatments Being Tested

Cabotegravir Tablets, for oral use.Cabotegravir Extended-Release Injectable Suspension, for intramuscular use.Tenofovir disoproxil/Emtricitabine 300mg/200mg fixed-dose combination tablets, for oral use Rectal Biopsies

A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects

PHASE1

This is a single-center, randomized, open-label, 3 parallel treatment study...

Status

Completed

Location

GSK Investigational Site

Start Date

2013-01

Trial ID

NCT01754116

Treatments Being Tested

GSK1265744 30 mg oral Midazolam 3 mg oral + GSK1265744 30mg oral GSK1265744 400 mg (200 nm)GSK1265744 400 mg (1 micro m)GSK1265744 400 mg (5 micro m)

Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy Subjects

PHASE1

CAB is an integrase inhibitor that is currently in Phase 2 clinical trials ...

Status

Completed

Location

GSK Investigational Site

Start Date

2015-07

Trial ID

NCT02411435

Treatments Being Tested

CAB RIF

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects

PHASE1

LAI115428 is a Phase I, randomized, repeat dose escalation study to determi...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-05

Trial ID

NCT01593046

Treatments Being Tested

GSK1265744 Oral GSK1265744 LAP 800mg intramuscular injection GSK1265744 LAP 200mg subcutaneous injection GSK1265744 LAP 200mg intramuscular injection GSK1265744 LAP 400mg intramuscular injection TMC278 LA 1200mg intramuscular injection TMC278 LA 600mg intramuscular injection GSK1265744 LAP 800mg intramuscular injection

A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects

PHASE1

This will be a single-center, two-cohort, three-period study in healthy adu...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-11

Trial ID

NCT01467531

Treatments Being Tested

Dolutegravir Rlipivirine GSK1265744

Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction

PHASE1

This study is being conducted to comply with the Food and Drug Administrati...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-01

Trial ID

NCT02027454

Treatments Being Tested

GSK1265744 GSK1265744 matching placebo Moxifloxacin

Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures

N/A

This study aims to characterize Swiss HIV Cohort Study participants initiat...

Status

Unknown

Location

University Hospital Zurich

Start Date

2022-03-01

Trial ID

NCT06405464

Treatments Being Tested

VOCABRIA 30Mg Tablet EDURANT 25Mg Tablet Cabotegravir Injectable Suspension Rilpivirine Injectable Suspension Intact proviral DNA assay Full-length sequencing

Improving HIV-1 Control in Africa with Long Acting Antiretrovirals

PHASE3

IMPALA is a randomized, open-label, multicenter, interventional study of 54...

Status

Active Not Recruiting

Location

Jaramogi Oginga Odinga Teaching & Referral Hospital

Start Date

2022-12-08

Trial ID

NCT05546242

Treatments Being Tested

Cabotegravir/Rilpivirine Antiretroviral

Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)

PHASE2

The purpose of this randomized, double-blinded study is to test the safety ...

Status

Completed

Location

GSK Investigational Site

Start Date

2009-06-09

Trial ID

NCT00920426

Treatments Being Tested

GSK1265744 30mg Placebo GSK1265744 5mg

Previous Next